Skip to main content
. 2020 Dec 28;7(2):127–131. doi: 10.1016/j.aace.2020.11.028

Fig 3.

Fig 3

Continuous glucose monitor tracing for 3 consecutive days after the patient had discontinued alpelisib, empagliflozin, and insulin therapy.